Sudeep Pharma balance sheet

As of Sep 2026

Total assets: ₹1,329cr+34.5% on Sep 2025
Shareholders' equity: ₹973cr+31.7% on Sep 2025
Total debt: ₹188cr+33.3% on Sep 2025
Cash and investments: ₹53.8cr+3.2% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026

Non-current assets
	401	224
	53.8	178
	43.9	—
	67.5	68.2
	0.1	0.2
	11.8	6.6
	4.7	19.5
	4.7	19.5
	1.1	0.5
	21.9	53.5
	605	551
Current assets
	275	216
	246	228
	53.8	26.7
	61.3	87.9
	5.4	0.3
	81.8	5.3
	448	348
	60.1	60.1
	723	624
	1,329	1,175
Equity
	11.3	11.3
	946	872
	957	883
	15.5	14.8
	973	898
Liabilities
	62.4	34.3
	31.5	29.8
	93.9	64.0
	0.6	0.0
	12.4	9.4
	1.3	1.3
	107	74.8
	125	114
	97.6	68.4
	14.0	8.0
	237	190
	0.9	1.2
	5.4	1.0
	5.6	9.3
	249	202
	356	277
	1,329	1,175
Trade payables — MSME split
	4.4	1.3
	93.2	67.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals

₹ CrorePeersSUDARSCHEM STYRENIX SHARDACROP REFEX RCF RALLIS RAIN PRIVISCLMcap ₹12,764 Cr

View

In ₹ Crore except Per Share As of	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	224.0	400.6
+ Capital Work-in-Progress	178.4	53.8
+ Investment Property	—	43.9
+ Goodwill	68.2	67.5
+ Other Intangibles	0.2	0.1
+ Intangibles under Development	6.6	11.8
+ Other Non-current Financial Assets	19.5	4.7
Non-current Financial Assets	19.5	4.7
+ Deferred Tax Assets	0.5	1.1
+ Other Non-current Assets	53.5	21.9
Total Non-current Assets	550.9	605.3
Current Assets
+ Inventories	216.0	274.9
+ Trade Receivables	227.5	246.1
+ Cash & Cash Equivalents	26.7	53.8
+ Other Bank Balances	87.9	61.3
+ Short-term Loans	0.3	5.4
+ Other Current Financial Assets	5.3	81.8
Current Financial Assets	347.8	448.4
+ Other Current Assets	60.1	60.1
Total Current Assets	624.0	723.3
Total Assets	1,174.9	1,328.6
Equity
+ Equity Share Capital	11.3	11.3
+ Other Equity / Reserves	872.0	946.0
Equity — Owners of Parent	883.3	957.3
+ Minority Interest	14.8	15.5
Total Equity	898.1	972.8
Liabilities
+ Borrowings — Non-current	34.3	62.4
+ Other Non-current Financial Liab	29.8	31.5
Non-current Financial Liabilities	64.0	93.9
+ Provisions — Non-current	0.0	0.6
+ Deferred Tax Liabilities	9.4	12.4
+ Other Non-current Liabilities	1.3	1.3
Non-current Liabilities	74.8	106.9
+ Borrowings — Current	114.0	125.2
+ Trade Payables	68.4	97.6
+ Other Current Financial Liab	8.0	14.0
Current Financial Liabilities	190.4	236.9
+ Provisions — Current	1.2	0.9
+ Current Tax Liabilities	1.0	5.4
+ Other Current Liabilities	9.3	5.6
Current Liabilities	202.0	248.9
Total Liabilities	276.8	355.8
Total Equity & Liabilities	1,174.9	1,328.6
Trade Payables — MSME split
+ Dues to Micro & Small — Current	1.3	4.4
+ Dues to Other Creditors — Current	67.1	93.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.